{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:06:40Z","timestamp":1789589200208,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ophtha.2015.05.027","type":"journal-article","created":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T21:29:58Z","timestamp":1435440598000},"page":"1907-1916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma"],"prefix":"10.1016","volume":"122","clinical-trial-number":[{"clinical-trial-number":"nct01320085","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01801358","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Elon H.C.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-4334","authenticated-orcid":false,"given":"Marina","family":"Marinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drake","family":"Amundson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9 P.M.","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen H.W.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan E.E.","family":"Keunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Adamus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel J.F.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2015.05.027_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.soncn.2013.06.002","article-title":"Skin cancer: an overview of epidemiology and risk factors","volume":"29","author":"Gordon","year":"2013","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ophtha.2015.05.027_bib3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2015.05.027_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/PPO.0b013e31824bd256","article-title":"Metastatic uveal melanoma: biology and emerging treatments","volume":"18","author":"Woodman","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.ophtha.2015.05.027_bib5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ophtha.2015.05.027_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CMAR.S49494","article-title":"Treating advanced melanoma: current insights and opportunities","volume":"6","author":"Tronnier","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ophtha.2015.05.027_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.ophtha.2015.05.027_bib8","doi-asserted-by":"crossref","first-page":"e40439","DOI":"10.1371\/journal.pone.0040439","article-title":"Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype","volume":"7","author":"Ho","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2015.05.027_bib9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2015.05.027_bib10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2015.05.027_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2015.05.027_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib13","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.43","article-title":"Overall survival and biomarker results from a phase 2 study of MEK1\/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma","volume":"25","author":"van Herpen","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib14","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2015.05.027_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2015.05.027_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10633-008-9155-4","article-title":"ISCEV Standard for full-field clinical electroretinography (2008 update)","volume":"118","author":"Marmor","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-011-9259-0","article-title":"ISCEV standard for clinical electro-oculography (2010 update)","volume":"122","author":"Marmor","year":"2011","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-011-9296-8","article-title":"ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition)","volume":"124","author":"Hood","year":"2012","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib19","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.03","year":"2010"},{"key":"10.1016\/j.ophtha.2015.05.027_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaophthalmol.2014.976","article-title":"Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer","volume":"132","author":"McCannel","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume":"25","author":"Urner-Bloch","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.autrev.2009.01.002","article-title":"Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy","volume":"8","author":"Adamus","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ophtha.2015.05.027_bib23","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1167\/iovs.13-12050","article-title":"Anti-retinal antibodies in patients with macular telangiectasia type 2","volume":"54","author":"Zhu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2015.05.027_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archopht.126.3.432","article-title":"Autoantibodies against bestrophin in a patient with vitelliform paraneoplastic retinopathy and a metastatic choroidal malignant melanoma","volume":"126","author":"Eksandh","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.preteyeres.2009.04.002","article-title":"The spectrum of ocular phenotypes caused by mutations in the BEST1 gene","volume":"28","author":"Boon","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2015.05.027_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archophthalmol.2010.316","article-title":"Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis","volume":"129","author":"Koreen","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/clin.1996.0021","article-title":"The occurrence of serum autoantibodies against enolase in cancer\u2013associated retinopathy","volume":"78","author":"Adamus","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-008-0114-7","article-title":"Autoimmune retinopathy: a review and summary","volume":"30","author":"Heckenlively","year":"2008","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib29","first-page":"91","article-title":"Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy","volume":"34","author":"Milam","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2015.05.027_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0002-9394(02)01431-9","article-title":"Autoantibodies to transducin in a patient with melanoma-associated retinopathy","volume":"134","author":"Potter","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ijc.22384","article-title":"Mitofilin and titin as target antigens in melanoma-associated retinopathy","volume":"120","author":"Pfohler","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ophtha.2015.05.027_bib32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1055\/s-2005-858840","article-title":"Paraneoplastic vitelliform retinopathy associated with cutaneous or uveal melanoma and metastases","volume":"222","author":"Sotodeh","year":"2005","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2015.05.027_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0002-9394(01)01086-8","article-title":"Melanoma-associated retinopathy and recurrent exudative retinal detachments in a patient with choroidal melanoma","volume":"132","author":"Zacks","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib34","first-page":"1756","article-title":"Bilateral multifocal chorioretinopathy in a woman with cutaneous malignant melanoma","volume":"120","author":"Palmowski","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00006982-200404000-00028","article-title":"Multiple serous retinal detachments and subretinal deposits as the presenting signs of metastatic melanoma","volume":"24","author":"Jampol","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2015.05.027_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00006982-200308000-00002","article-title":"Acute exudative polymorphous vitelliform maculopathy syndrome","volume":"23","author":"Chan","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2015.05.027_bib37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.eye.6702949","article-title":"Paraneoplastic vitelliform retinopathy associated with metastatic choroidal melanoma","volume":"21","author":"Nieuwendijk","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2015.05.027_bib38","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archopht.125.8.1100","article-title":"Clinical and genetic heterogeneity in multifocal vitelliform dystrophy","volume":"125","author":"Boon","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2015.05.027_bib39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2012.09.057","article-title":"Autosomal recessive bestrophinopathy: differential diagnosis and treatment options","volume":"120","author":"Boon","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642015005102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642015005102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T04:55:02Z","timestamp":1537505702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642015005102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0161642015005102"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.027","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}